Lixte Biotechnology Holdings, Inc. (LIXT)
- Previous Close
3.2500 - Open
3.3250 - Bid --
- Ask --
- Day's Range
3.1931 - 3.3250 - 52 Week Range
1.5800 - 9.5000 - Volume
4,160 - Avg. Volume
572,535 - Market Cap (intraday)
7.333M - Beta (5Y Monthly) -0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6600 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
lixte.comRecent News: LIXT
Performance Overview: LIXT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIXT
Valuation Measures
Market Cap
7.24M
Enterprise Value
6.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
14.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.29
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-64.47%
Return on Equity (ttm)
-111.07%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.09M
Diluted EPS (ttm)
-2.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
4.2M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.4M